HighPoint Advisor Group’s Acorda Therapeutics ACOR Stock Holding History

HighPoint Advisor Group’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-86	Closed	-$20K	–	406
2019 Q4	$20K	Sell	86 -1	-1%	-$252	﹤0.01%	368
2019 Q3	$24K	Sell	87 -4	-4%	-$2.17K	0.01%	486
2019 Q2	$71K	Buy	+91	New	+$112K	0.02%	475
2018 Q3	–	Sell	-63	Closed	-$212K	–	371
2018 Q2	$212K	Buy	63 +5	+9%	+$15.3K	0.06%	302
2018 Q1	$210K	Buy	+58	New	+$174K	0.06%	299
2016 Q1	–	Sell	-81	Closed	-$369K	–	244
2015 Q4	$369K	Sell	81 -20	-20%	-$87.4K	0.24%	125
2015 Q3	$323K	Buy	101 +2	+2%	+$7.76K	0.36%	102
2015 Q2	$394K	Buy	99 +11	+13%	+$42.5K	0.61%	56
2015 Q1	$360K	Buy	+88	New	+$403K	0.55%	56

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HighPoint Advisor Group's ACOR Position: Q1 2020 in Review

HighPoint Advisor Group sold out of Acorda Therapeutics (ACOR) in Q1 2020, closing a stake of 86 shares — an estimated $20K sold.

HighPoint Advisor Group first reported a position in ACOR in Q1 2015 and held it in 9 quarters. The position peaked at $394K in Q2 2015. 106 funds tracked by Wall St. Rank hold ACOR as of Q1 2020.

HighPoint Advisor Group reported no remaining Acorda Therapeutics position as of Q1 2020 after selling out during the quarter.
HighPoint Advisor Group sold 86 Acorda Therapeutics shares in Q1 2020, an estimated $20K.
HighPoint Advisor Group first reported a position in Acorda Therapeutics in Q1 2015 and held it in 9 quarters.
HighPoint Advisor Group's Acorda Therapeutics position peaked at $394K in Q2 2015.
106 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2020.

Based on HighPoint Advisor Group's 13F filing for Q1 2020, filed 27 Apr 2020.